The Role of Chlorambusilobenituzumab in CLL Treatment

Most patients are in their 60s and it is a slightly younger group that is enrolling in these studies. So you kind of have to go into this older patient, unfit population to be able to do that. That's not a great answer. I think the recognition that these drugs are there and available or out there, I think there is a lot of conversion occurring. But I don't have a great answer of why it persists.